目的探讨含亮氨酸重复序列G-蛋白偶联受体5(1eucine-rich repeat-containing G protein coupled receptor 5,Lgr5)及CD44在卵巢癌中的表达及其与预后的关系。方法选取2006年5月至2010年1月住院并接受手术治疗的卵巢癌患者140例,选取同...目的探讨含亮氨酸重复序列G-蛋白偶联受体5(1eucine-rich repeat-containing G protein coupled receptor 5,Lgr5)及CD44在卵巢癌中的表达及其与预后的关系。方法选取2006年5月至2010年1月住院并接受手术治疗的卵巢癌患者140例,选取同期本院因卵巢良性病变行肿物剥除或附件切除的40例患者作为对照,应用免疫组化(S-P)方法检测140例卵巢癌组织(卵巢癌组)、140例卵巢癌癌旁组织(癌旁组)、正常卵巢组织40例(正常组)中的Lgr5及CD44蛋白表达,分析其与卵巢癌患者临床病理指标的关系。结果 (1)Lgr5在正常卵巢组织、癌旁组织和卵巢癌中的阳性率分别为5.0%、18.3%和95.7%,差异具有统计学意义(F=24.581,P=0.001);CD44在正常卵巢组织、癌旁组织和卵巢癌中的阳性率分别为7.5%、15.7%和90.0%,差异具有统计学意义(P<0.05)。(2)Lgr5表达与肿瘤分化程度、淋巴结转移及TNM分期有关(P<0.05)。CD44表达与肿瘤分化程度、浸润深度、淋巴结转移及TNM分期有关(P<0.05)。(3)Lgr5及CD44存在正相关性(r=0.3,P<0.05)。(4)Lgr5高表达者(+++)和低表达者(+)^(++)5年总生存率分别为29.2%和51.2%(HR=11.637,95%CI:4.351~18.439;P=0.002);CD44高表达者(+++)和低表达者(+)^(++)5年总生存率分别为35.3%和41.3%(HR=10.142,95%CI:4.285~17.013;P=0.006)。结论 Lgr5及CD44的增强表达与卵巢癌侵袭性增强有密切关系,其表达可作为判断卵巢癌患者预后的指标。展开更多
The intestinal epithelial lining plays a central role in the digestion and absorption of nutrients,but exists in a harsh luminal environment that necessitates continual renewal.This renewal process involves epithelial...The intestinal epithelial lining plays a central role in the digestion and absorption of nutrients,but exists in a harsh luminal environment that necessitates continual renewal.This renewal process involves epithelial cell proliferation in the crypt base and later cell migration from the crypt base to the luminal surface.This process is dependent on multi-potent progenitor cells,or stem cells,located in each crypt.There are about 4 to 6 stem cells per crypt,and these stem cells are believed to generate distinct end-differentiated epithelial cell types,including absorptive cells,goblet cells,enteroendocrine cells and Paneth cells,while also maintaining their own progenitor cell state.Earlier studies suggested that intestinal stem cells were located either in the crypt base interspersed between the Paneth cells [i.e.crypt base columnar(CBC) cell model] or at an average position of 4 cells from the crypt base [i.e.label-retaining cells(LRC +4) model].Recent studies have employed biomarkers in the in vivo mammalian state to more precisely evaluate the location of these progenitor cells in the intestinal crypt.Most notable of these novel markers are Lgr5,a gene that encodes a G-protein-coupled receptor with expression restricted to CBC cells,and Bmi 1,which encodes a chromatin remodeling protein expressed by LRC.These studies raise the possibility that there may be separate stem cell lines or different states of stem cell activation involved in the renewal of normal mammalian intestinal tract.展开更多
文摘目的探讨含亮氨酸重复序列G-蛋白偶联受体5(1eucine-rich repeat-containing G protein coupled receptor 5,Lgr5)及CD44在卵巢癌中的表达及其与预后的关系。方法选取2006年5月至2010年1月住院并接受手术治疗的卵巢癌患者140例,选取同期本院因卵巢良性病变行肿物剥除或附件切除的40例患者作为对照,应用免疫组化(S-P)方法检测140例卵巢癌组织(卵巢癌组)、140例卵巢癌癌旁组织(癌旁组)、正常卵巢组织40例(正常组)中的Lgr5及CD44蛋白表达,分析其与卵巢癌患者临床病理指标的关系。结果 (1)Lgr5在正常卵巢组织、癌旁组织和卵巢癌中的阳性率分别为5.0%、18.3%和95.7%,差异具有统计学意义(F=24.581,P=0.001);CD44在正常卵巢组织、癌旁组织和卵巢癌中的阳性率分别为7.5%、15.7%和90.0%,差异具有统计学意义(P<0.05)。(2)Lgr5表达与肿瘤分化程度、淋巴结转移及TNM分期有关(P<0.05)。CD44表达与肿瘤分化程度、浸润深度、淋巴结转移及TNM分期有关(P<0.05)。(3)Lgr5及CD44存在正相关性(r=0.3,P<0.05)。(4)Lgr5高表达者(+++)和低表达者(+)^(++)5年总生存率分别为29.2%和51.2%(HR=11.637,95%CI:4.351~18.439;P=0.002);CD44高表达者(+++)和低表达者(+)^(++)5年总生存率分别为35.3%和41.3%(HR=10.142,95%CI:4.285~17.013;P=0.006)。结论 Lgr5及CD44的增强表达与卵巢癌侵袭性增强有密切关系,其表达可作为判断卵巢癌患者预后的指标。
文摘The intestinal epithelial lining plays a central role in the digestion and absorption of nutrients,but exists in a harsh luminal environment that necessitates continual renewal.This renewal process involves epithelial cell proliferation in the crypt base and later cell migration from the crypt base to the luminal surface.This process is dependent on multi-potent progenitor cells,or stem cells,located in each crypt.There are about 4 to 6 stem cells per crypt,and these stem cells are believed to generate distinct end-differentiated epithelial cell types,including absorptive cells,goblet cells,enteroendocrine cells and Paneth cells,while also maintaining their own progenitor cell state.Earlier studies suggested that intestinal stem cells were located either in the crypt base interspersed between the Paneth cells [i.e.crypt base columnar(CBC) cell model] or at an average position of 4 cells from the crypt base [i.e.label-retaining cells(LRC +4) model].Recent studies have employed biomarkers in the in vivo mammalian state to more precisely evaluate the location of these progenitor cells in the intestinal crypt.Most notable of these novel markers are Lgr5,a gene that encodes a G-protein-coupled receptor with expression restricted to CBC cells,and Bmi 1,which encodes a chromatin remodeling protein expressed by LRC.These studies raise the possibility that there may be separate stem cell lines or different states of stem cell activation involved in the renewal of normal mammalian intestinal tract.
